Johnson & Johnson
Trade Johnson & Johnson 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About JNJ
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments.
JNJ Key Statistics
JNJ News
recently experienced a 12% price increase over the last quarter, largely driven by significant announcements regarding its clinical trials, particularly the ANT...
William Blair analyst Matthew Phipps last night upgraded Genmab (GMAB) to Outperform from Market Perform without a price target. after the company announced tha...
Morgan Stanley says intra-day pressure on Genmab (GMAB) of greater than 5% after Genmab announced that partner Johnson & Johnson (JNJ) has decided to not exerci...
Analyst ratings
52%
of 23 ratingsMore JNJ News
Genmab A/S (Nasdaq: GMAB) said on Monday that Johnson & Johnson (J&J) has decided not to exercise its option to obtain a worldwide license for the development,...
10:18 EDT Genmab (GMAB) falls 7% to $22.44 after J&J declines option on HexaBody-CD38 Published first on TheFly – the ultimate source for real-time, market-mov...
Johnson & Johnson announced positive topline results from ANTHEM-UC, a Phase 2b study of icotrokinra, the first investigational targeted oral peptide that selec...
Johnson & Johnson announced new icotrokinra, JNJ-2113, data from its comprehensive Phase 3 clinical program and the start of the first-ever head-to-head study i...
On Friday, Johnson & Johnson JNJ decided to discontinue the Phase 3 VENTURA development program evaluating aticaprant, a kappa opioid receptor (KOR) antagonist,...
Stifel downgraded Neumora Therapeutics (NMRA) to Hold from Buy with a price target of $2, down from $6. The shares are now “much harder to defend” after Johnson...
BofA raised the firm’s price target on Johnson & Johnson (JNJ) to $171 from $159 and keeps a Neutral rating on the shares. For the last several weeks, markets h...